Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/ hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 70, Issue 12, 2009, Pages 1652-1661

  Adler, Lenard A ^a   Weisler, Richard H ^b,c   Goodman, David W ^d   Hamdani, Mohamed ^e   Niebler, Gwendolyn E ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIURETIC AGENT; LISDEXAMFETAMINE;

ADULT; ARM DISCOMFORT; ARM DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; SINUS TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PRODRUGS; TREATMENT OUTCOME;

EID: 74549198480     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05335pur     Document Type: Article

References (50)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248. doi:10.1016/S0140-6736(05)66915-2 PubMed
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948. doi:10.1176/appi.ajp.164.6.942 PubMed
3. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria, pt 1: an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29(4):546-557. PubMed
4. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111(2):279-289. doi:10.1037/0021-843X.111.2.279 PubMed
5. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.1176/appi.ajp. 163.4.716 PubMed
6. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301-1313. PubMed
7. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl 2):26S-49S
8. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65(suppl 3):27-37. PubMed
9. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434-443. PubMed
10. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782. doi:10.1001/archpsyc.58.8.775 PubMed
11. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639. PubMed
12. Fallu A, Richard C, Prinzo R, et al. Does OROS-methylphenidate improve core symptoms and deficits in executive function? results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22(12):2557-2566. doi:10.1185/030079906X154132 PubMed
13. Faraone SV, Spencer TJ, Montano CB, et al. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164(11):1221-1226. doi:10.1001/archinte.164.11.1221 PubMed
14. Findling RL, Biederman J, Wilens TE, et al; SLI381.301 and .302 Study Groups. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147(3):348-354. doi:10.1016/j.jpeds.2005.03.014 PubMed
15. Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(suppl 20):35-43. PubMed
16. Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999;38(8):1047-1050. PubMed
17. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-1448. doi:10.1056/NEJMp068049 PubMed
18. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259. PubMed
19. Biederman J, Mick E, Surman C, et al. A randomized, placebo- controlled trial of OROS methylphenidate in adults with attention- deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835. doi:10.1016/j.biopsych. 2005.09.011 PubMed
20. Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2009.
21. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
22. Adderall XR [package insert]. Wayne, PA: Shire US Inc.; 2009.
23. Vyvanse [package insert]. Wayne, PA: Shire US Inc.; 2009.
24. Vetter VL, Elia J, Erickson C, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/ hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423. doi:10.1161/CIRCULATIONAHA.107.189473 PubMed
25. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-453. doi:10.1542/peds.2008-1573 PubMed
26. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17(1):61-72. doi:10.1007/s11065-006-9017-3 PubMed
27. Pennick M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Poster presented at: 64th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry; May 14-16, 2009; Vancouver, British Columbia, Canada.
28. Pennick M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Poster presented at: 49th Annual Meeting of the New Clinical Drug Evaluation Unit; June 29-July 2, 2009; Hollywood, FL.
29. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373. doi:10.4088/JCP.v69n0903 PubMed
30. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201. doi:10.1016/j.psc.2003.12.003 PubMed
31. ADHD-RS Initial Evaluation. http://www.askdrjones.com./wp-content/ uploads/patientforms/ADHD%20Screening-Initial%20Eval.pdf. Accessed August 12, 2009.
32. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14. http://www.fda.gov/cder/guidance/6922fnl.htm. Accessed March 8, 2007.
33. Moss AJ. Drugs that prolong the QT interval: regulatory and QT measurement issues from the United States and European perspectives. Ann Noninvasive Electrocardiol. 1999;4(3):255-256. doi:10.1111/j.1542-474X.1999. tb00208.x
34. US Dept Health and Human Services. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7 Express (for Primary Care). http://www.nhlbi.nih.gov/ guidelines/hypertension/jncintro.htm. Accessed December 9, 2008.
35. Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53(1):96-104. PubMed
36. Marshall TP. Blood pressure variability: the challenge of variation. Am J Hypertens. 2008;21(1):3-4. doi:10.1038/ajh.2007.20 PubMed
37. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration. Rockville, Md: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:218-222.
38. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5): 456-463. doi:10.1016/j.biopsych.2004.11.043 PubMed
39. Biederman J, Spencer TJ, Wilens TE, et al; SLI381.304 study group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10 (suppl 20):16-25. PubMed
40. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818-827. doi:10.1161/HYPERTENSIONAHA.108.113357 PubMed
41. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989. doi:10.1016/j.biopsych.2007.11.008 PubMed
42. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-247. doi:10.1097/JCP. 0b013e3181a390ce PubMed
43. Spencer TJ, Adler LA, McGough JJ, et al; Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380-1387. doi:10.1016/j.biopsych.2006.07.032 PubMed
44. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22(3):213-237. doi:10.2165/00023210- 200822030-00003 PubMed
45. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. doi:10.1016/S0006-3223(02)01671-2 PubMed
46. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44-50. doi:10.1097/JCP.0b013e318192e4a0 PubMed
47. Metadate CD [package insert]. Smyrna, GA: UCB, Inc.; 2008.
48. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
49. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118(3):1215-1219. doi:10.1542/peds.2006-0942 PubMed
50. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14,786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165-1172. PubMed